「galegenimab」熱門搜尋資訊

galegenimab

「galegenimab」文章包含有:「AStudyAssessingtheSafety」、「Anti」、「Galegenimab(FHTR2163)」、「Galegenimab-Genentech」、「galegenimab」、「VIDEO」、「視網膜地圖狀萎縮藥開發難?羅氏撤二期候選抗體藥」

查看更多
Provide From Google
A Study Assessing the Safety
A Study Assessing the Safety

https://clinicaltrials.gov

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 ...

Provide From Google
Anti
Anti

https://www.abeomics.com

Anti-HTRA1(galegenimab biosimilar) mAb ; Clonality : Monoclonal ; Reactivity : Human ; Amount : 100 µg ; Isotype : IgG1 ; Purification : Purified from cell culture ...

Provide From Google
Galegenimab (FHTR 2163)
Galegenimab (FHTR 2163)

https://www.medchemexpress.com

Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular ...

Provide From Google
Galegenimab - Genentech
Galegenimab - Genentech

https://adisinsight.springer.c

Galegenimab (formerly RO 7171009) intravitreal injection was being developed by Genentech (a subsidiary of Roche), for the treatment of patients with ...

Provide From Google
galegenimab
galegenimab

https://www.guidetopharmacolog

Comment: Galegenimab is the INN that has been assigned to Genentech's anti-HTRA1 (HtrA serine peptidase 1) Fab antibody [6]. The antibody and its use are ...

Provide From Google
VIDEO
VIDEO

https://www.healio.com

Provide From Google
視網膜地圖狀萎縮藥開發難?羅氏撤二期候選抗體藥
視網膜地圖狀萎縮藥開發難?羅氏撤二期候選抗體藥

https://news.gbimonthly.com

除了galegenimab以外,羅氏仍然有一些用於治療地圖狀萎縮的選擇,包括子公司基因泰克(Genentech)管理的1項臨床一期候選藥物,以及羅氏合作夥伴Lineage ...

最新搜尋趨勢